Relationship between Inflammatory and Biological Markers and Lung Cancer
Abstract
:1. Introduction
2. Materials and Methods
2.1. Measurements
2.2. Lung Cancer Staging
2.3. Histopathological Types of Lung Cancer
2.4. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69–90. [Google Scholar] [CrossRef] [PubMed]
- Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature 2008, 454, 436–444. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Walsh, S.R.; Cook, E.J.; Goulder, F.; Justin, T.A.; Keeling, N.J. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J. Surg. Oncol. 2005, 91, 181–184. [Google Scholar] [CrossRef] [PubMed]
- Ceylan, C.; Camtosun, A.; Doluoglu, O.G.; Tasdemir, S.; Keles, I.; Aglamis, E.; Tatar, C.A. Emphasis of neutrophil-to-lymphocyte ratio in non-metastatic renal cell carcinoma. Urologia 2014, 81, 51–56. [Google Scholar] [CrossRef] [PubMed]
- Unal, D.; Eroglu, C.; Kurtul, N.; Oguz, A.; Tasdemir, A. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac. J. Cancer Prev. 2013, 14, 5237–5242. [Google Scholar] [CrossRef] [PubMed]
- Chi, P.D.; Liu, W.; Chen, H.; Zhang, J.P.; Lin, Y.; Zheng, X.; Liu, W.; Dai, S. High-density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with C-reactive protein level in non-small cell lung carcinoma. PLoS ONE 2014, 9. [Google Scholar] [CrossRef] [PubMed]
- Goldstraw, P.; Chansky, K.; Crowley, J.; Rami-Porta, R.; Asamura, H.; Eberhardt, W.E.; Nicholson, A.G.; Groome, P.; Mitchell, A.; Bolejack, V.; et al. The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J. Thorac. Oncol. 2016, 11, 39–51. [Google Scholar] [CrossRef] [PubMed]
- Shang, K.; Bai, Y.-P.; Wang, C.; Gu, H.Y.; Du, X.; Zhou, X.Y.; Zheng, C.L.; Chi, Y.Y.; Mukaida, N.; Li, Y.Y. Crucial involvement of tumor-associated neutrophils in the regulation of chronic colitis-associated carcinogenesis in mice. PLoS ONE 2012, 7. [Google Scholar] [CrossRef] [PubMed]
- Van Egmond, M.; Bakema, J.E. Neutrophils as effector cells for antibody-based immunotherapy of cancer. Semin. Cancer Biol. 2013, 23, 190–199. [Google Scholar] [CrossRef] [PubMed]
- Sagiv, J.Y.; Michaeli, J.; Assi, S.; Mishalian, I.; Kisos, H.; Levy, L.; Damti, P.; Lumbroso, D.; Polyansky, L.; Sionov, R.V.; et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep. 2015, 10, 562–573. [Google Scholar] [CrossRef] [PubMed]
- Sionov, R.V.; Fridlender, Z.G.; Granot, Z. The multifaceted roles neutrophils play in the tumor microenvironment. Cancer Microenviron. 2015, 8, 125–158. [Google Scholar] [CrossRef] [PubMed]
- Margolis, K.L.; Rodabough, R.J.; Thomson, C.A.; Lopez, A.M.; McTiernan, A. Women’s health initiative research group: Prospective study of leukocyte count as a predictor of incident breast, colorectal, endometrial, and lung cancer and mortality in postmenopausal women. Arch. Intern. Med. 2007, 167, 1837–1844. [Google Scholar] [CrossRef] [PubMed]
- Fridlender, Z.G.; Albelda, S.M. Tumor-associated neutrophils: Friend or foe? Carcinogenesis 2012, 33, 949–955. [Google Scholar] [CrossRef] [PubMed]
- Trellakis, S.; Farjah, H.; Bruderek, K.; Dumitru, C.A.; Hoffmann, T.K.; Lang, S.; Brandau, S. Peripheral blood neutrophil granulocytes from patients with head and neck squamous cell carcinoma functionally differ from their counterparts in healthy donors. Int. J. Immunopathol. Pharmacol. 2011, 24, 683–693. [Google Scholar] [CrossRef] [PubMed]
- Caruso, R.A.; Bellocco, R.; Pagano, M.; Bertoli, G.; Rigoli, L.; Inferrera, C. Prognostic value of intratumoral neutrophils in advanced gastric carcinoma in a high-risk area in northern Italy. Mod. Pathol. 2002, 15, 831–837. [Google Scholar] [CrossRef] [PubMed]
- Unsal, E.; Atalay, F.; Atikcan, S.; Yilmaz, A. Prognostic significance of haemostatic parameters in patients with lung cancer. Respir. Med. 2004, 98, 93–98. [Google Scholar] [CrossRef] [PubMed]
- Van Doormaal, F.F.; Raskob, G.E.; Davidson, B.L.; Decousus, H.; Gallus, A.; Lensing, A.W.; Piovella, F.; Prins, M.H.; Büller, H.R. Treatment of venous thromboembolism in patients with cancer: Subgroup analysis of the Matisse clinical trials. Thromb. Haemost. 2009, 101, 762–769. [Google Scholar] [CrossRef] [PubMed]
- Pedersen, L.M.; Milman, N. Diagnostic significance of platelet count and other blood analyses in patients with lung cancer. Oncol. Rep. 2003, 10, 213–216. [Google Scholar] [CrossRef] [PubMed]
- Constantini, V.; Zacharski, L.R.; Moritz, T.E.; Edwards, R.L. The platelet count in carcinoma of the lung and colon. Thromb. Haemost. 1990, 64, 501–505. [Google Scholar]
- Pedersen, L.M.; Milman, N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur. Respir. J. 1996, 9, 1826–1830. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Varol, E.; Icli, A.; Uysal, B.A.; Ozaydin, M. Platelet indices in patients with acute pulmonary embolism. Scand. J. Clin. Lab. Investig. 2011, 71, 163–167. [Google Scholar] [CrossRef] [PubMed]
- Yetkin, E. Mean platelet volume not so far from being a routine diagnostic and prognostic measurement. Thromb. Haemost. 2008, 100, 3–4. [Google Scholar] [CrossRef] [PubMed]
- Kumagai, S.; Tokuno, J.; Ueda, Y.; Marumo, S.; Shoji, T.; Nishimura, T.; Fukui, M.; Huang, C.L. Prognostic significance of preoperative mean platelet volume in resected non-small-cell lung cancer. Mol. Clin. Oncol. 2015, 3, 197–201. [Google Scholar] [CrossRef] [PubMed]
- Karagöz, B.; Alacacıoğlu, A.; Bilgi, O.; Demirci, H.; Özgün, A.; Erikçi, A.A.; Sayan, Ö.; Yılmaz, B.; Kandemir, E.G. Platelet count and platelet distribution width increase in lung cancer patients. Anatol. J. Clin. Investig. 2009, 3, 32–34. [Google Scholar]
- Mutlu, H.; Artis, T.A.; Erden, A.; Akca, Z. Alteration in mean platelet volume and platicrit values in patients with cancer that developed thrombosis. Clin. Appl. Thromb. Hemost. 2012, 19, 331–333. [Google Scholar] [CrossRef] [PubMed]
- Sarraf, K.M.; Belcher, E.; Raevsky, E.; Nicholson, A.G.; Goldstraw, P.; Lim, E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 2009, 137, 425–428. [Google Scholar] [CrossRef] [PubMed]
- Ohno, Y.; Nakashima, J.; Ohori, M.; Hatano, T.; Tachibana, M. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J. Urol. 2010, 184, 873–878. [Google Scholar] [CrossRef] [PubMed]
- Holmes, C.E.; Levis, J.E.; Ornstein, D.L. Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis. Clin. Exp. Metastasis 2009, 26, 653–661. [Google Scholar] [CrossRef] [PubMed]
- Kemal, Y.; Yucel, I.; Ekiz, K.; Demirag, G.; Yilmaz, B.; Teker, F.; Ozdemir, M. Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosis. Asian Pac. J. Cancer Prev. 2014, 15, 2651–2654. [Google Scholar] [CrossRef] [PubMed]
- Kotani, K.; Sekine, Y.; Ishikawa, S.; Ikpot, I.Z.; Suzuki, K.; Remaley, A.T. High-density lipoprotein and prostate cancer: An overview. J. Epidemiol. 2013, 23, 313–319. [Google Scholar] [CrossRef] [PubMed]
- Guo, E.; Chen, L.; Xie, Q.; Chen, J.; Tang, Z.; Wu, Y. Serum HDL-C as a potential biomarker for nodal stages in gastric cancer. Ann. Surg. Oncol. 2007, 14, 2528–2534. [Google Scholar] [CrossRef] [PubMed]
Group 1 (mean ± SD) | Group 2 (mean ± SD) | p Value | |
---|---|---|---|
Age (years) | 58.85 ± 9.26 | 51.82 ± 8.99 | 0.14 |
Plt, ×10³/μL | 330 ± 104.4 | 233 ± 371.8 | 0.03 * |
MPV, fL | 7.45 ± 0.80 | 8.79 ± 0.70 | 0.04 * |
PCT, % | 0.27 ± 0.07 | 0.21 ± 0.04 | 0.03 * |
PDW, % | 15.19 ± 2.24 | 14.77 ± 1.95 | 0.53 |
Neutrophile, μL | 6548 ± 3141 | 3595 ± 768 | 0.01 * |
Lymphocyte, μL | 1928 ± 682 | 2924 ± 811 | 0.02 * |
NLR | 3.48 ± 0.31 | 0.76 ± 0.08 | 0.0001 * |
PLR | 105 ± 9.21 | 23.90 ± 3.38 | 0.0001 * |
WBC, μL | 9500 ± 3428 | 7100 ± 1313 | 0.72 |
Total protein, g/L | 6.9 ± 0.7 | 7.0 ± 0.4 | 0.17 |
Albumin, g/L | 3.5 ± 0.5 | 4.0 ± 0.3 | <0.001 * |
Total Cholesterol, mmol/L | 163.7 ± 31 | 163.9 ± 21.9 | 0.93 |
Triglyceride, mmol/L | 116.9 ± 42 | 100.9 ± 27.7 | 0.02 * |
HDL, mmol/L | 34.2 ± 7.7 | 47.7 ± 5.0 | <0.001 * |
LDL, mmol/L | 104.3 ± 27 | 97.2 ± 20.2 | 0.15 |
VLDL, mmol/L | 24.7 ± 12.3 | 19.9 ± 7.0 | 0.02 * |
CRP, mg/L | 12.9 ± 10.9 | 0.45 ± 0.2 | <0.001 * |
Histopathological Type (p Value) | Advanced- Stage (TNM) (p Value) | |
---|---|---|
Plt, ×10³/μL | 0.23 | 0.02 * |
MPV, fL | 0.46 | 0.04 * |
PCT, % | 0.33 | 0.01 * |
PDW, % | 0.53 | 0.06 |
Neutrophile, μL | 0.47 | 0.09 |
Lymphocyte, μL | 0.49 | 0.02 * |
NLR | 0.59 | 0.03 * |
PLR | 0.34 | 0.001 * |
Total protein, g/L | 0.87 | 0.82 |
Albumin, g/L | 0.16 | 0.02 * |
Total Cholesterol, mmol/L | 0.55 | 0.34 |
Triglyceride, mmol/L | 0.32 | 0.76 |
HDL, mmol/L | 0.80 | 0.001 * |
LDL, mmol/L | 0.60 | 0.98 |
VLDL, mmol/L | 0.40 | 0.60 |
CRP, mg/L | 0.78 | 0.004 * |
NLR | PLR | HDL | Albumin | CRP | |
---|---|---|---|---|---|
r | r | r | r | r | |
Stage (TNM) | 0.47 ** | 0.38 ** | −0.32 ** | −0.37 ** | 0.49 ** |
Histopathologic Type | NS | NS | NS | NS | NS |
Metastasis | 0.43 ** | 0.33 ** | −0.35 ** | −0.31 ** | 0.48 ** |
HDL | −0.29 * | −0.21 * | 0.51 ** | −0.39 ** | |
Albumin | −0.32 ** | −0.25 * | 0.51 ** | −0.35 ** | |
CRP | 0.42 ** | 0.36 ** | −0.39 ** | −0.35 ** |
Ratio | Sensitivity (%) | Specificity (%) | |
---|---|---|---|
NLR | 1.5 * | 86 * | 92 * |
2 | 69 | 98 | |
2.5 | 50 | 100 | |
PLR | 106.5 | 85 | 82 |
112.5 * | 84 * | 90 * | |
120.5 | 78 | 92 |
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Şahin, F.; Aslan, A.F. Relationship between Inflammatory and Biological Markers and Lung Cancer. J. Clin. Med. 2018, 7, 160. https://doi.org/10.3390/jcm7070160
Şahin F, Aslan AF. Relationship between Inflammatory and Biological Markers and Lung Cancer. Journal of Clinical Medicine. 2018; 7(7):160. https://doi.org/10.3390/jcm7070160
Chicago/Turabian StyleŞahin, Füsun, and Ayşe Feyza Aslan. 2018. "Relationship between Inflammatory and Biological Markers and Lung Cancer" Journal of Clinical Medicine 7, no. 7: 160. https://doi.org/10.3390/jcm7070160